These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 24165088)
21. Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models. Visalli RJ; Natuk RJ; Kowalski J; Guo M; Blakeney S; Gangolli S; Cooper D Vaccine; 2014 Mar; 32(12):1398-406. PubMed ID: 24462481 [TBL] [Abstract][Full Text] [Related]
22. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Morello CS; Kraynyak KA; Levinson MS; Chen Z; Lee KF; Spector DH Vaccine; 2012 Oct; 30(46):6541-6550. PubMed ID: 22947141 [TBL] [Abstract][Full Text] [Related]
23. Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD. Baghian A; Chouljenko VN; D'Auvergne O; Newman MJ; Baghian S; Kousoulas KG J Med Microbiol; 2002 Apr; 51(4):350-357. PubMed ID: 11926742 [TBL] [Abstract][Full Text] [Related]
24. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. Awasthi S; Zumbrun EE; Si H; Wang F; Shaw CE; Cai M; Lubinski JM; Barrett SM; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM J Virol; 2012 Apr; 86(8):4586-98. PubMed ID: 22318147 [TBL] [Abstract][Full Text] [Related]
25. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. Gillgrass AE; Ashkar AA; Rosenthal KL; Kaushic C J Virol; 2003 Sep; 77(18):9845-51. PubMed ID: 12941893 [TBL] [Abstract][Full Text] [Related]
26. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. Morrison LA; Zhu L; Thebeau LG J Virol; 2001 Feb; 75(3):1195-204. PubMed ID: 11152492 [TBL] [Abstract][Full Text] [Related]
27. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. Halford WP; Püschel R; Gershburg E; Wilber A; Gershburg S; Rakowski B PLoS One; 2011 Mar; 6(3):e17748. PubMed ID: 21412438 [TBL] [Abstract][Full Text] [Related]
30. Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies. Stanfield BA; Pahar B; Chouljenko VN; Veazey R; Kousoulas KG Vaccine; 2017 Jan; 35(4):536-543. PubMed ID: 28017425 [TBL] [Abstract][Full Text] [Related]
32. Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice. Wang X; Xie G; Liao J; Yin D; Guan W; Pan M; Li J; Li Y Virol J; 2011 May; 8():232. PubMed ID: 21575169 [TBL] [Abstract][Full Text] [Related]
34. Prophylactic herpes simplex virus type 2 vaccine adjuvanted with a universal CD4 T cell helper peptide induces long-term protective immunity against lethal challenge in mice. Li X; Zhang S; Lei J; Zhu Y; Zhou X; Xiao J; Xiang T Int Immunopharmacol; 2018 Aug; 61():100-108. PubMed ID: 29857239 [TBL] [Abstract][Full Text] [Related]
35. Nonneutralizing antibody against the glycoprotein K of herpes simplex virus type-1 exacerbates herpes simplex virus type-1-induced corneal scarring in various virus-mouse strain combinations. Ghiasi H; Cai S; Slanina S; Nesburn AB; Wechsler SL Invest Ophthalmol Vis Sci; 1997 May; 38(6):1213-21. PubMed ID: 9152241 [TBL] [Abstract][Full Text] [Related]
36. Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus. Diaz FM; Knipe DM Virology; 2016 Jan; 488():61-7. PubMed ID: 26609935 [TBL] [Abstract][Full Text] [Related]
37. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus. Ramsey NLM; Visciano M; Hunte R; Loh LN; Burn Aschner C; Jacobs WR; Herold BC J Virol; 2020 Jun; 94(13):. PubMed ID: 32295919 [TBL] [Abstract][Full Text] [Related]
38. Role of CD8+ T cells and lymphoid dendritic cells in protection from ocular herpes simplex virus 1 challenge in immunized mice. Matundan H; Mott KR; Ghiasi H J Virol; 2014 Jul; 88(14):8016-27. PubMed ID: 24807710 [TBL] [Abstract][Full Text] [Related]
39. Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice. Vagvala SP; Thebeau LG; Wilson SR; Morrison LA J Virol; 2009 Jan; 83(2):953-60. PubMed ID: 18987142 [TBL] [Abstract][Full Text] [Related]
40. CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge. Yan Y; Hu K; Fu M; Deng X; Luo S; Tong L; Guan X; He S; Li C; Jin W; Du T; Zheng Z; Zhang M; Liu Y; Hu Q mSphere; 2021 Apr; 6(2):. PubMed ID: 33910988 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]